Remarkable response to crizotinib in a patient with advanced lung adenocarcinoma harboring the MPRIP-ROS1 fusion gene: A case report

IF 0.7 Q4 RESPIRATORY SYSTEM

Respiratory Medicine Case Reports Pub Date : 2025-01-01 DOI:10.1016/j.rmcr.2025.102243

Yasuyuki Kishikawa, Kohei Otsubo, Daisuke Shibahara, Yoshimasa Shiraishi, Yasuto Yoneshima, Eiji Iwama, Isamu Okamoto

{"title":"Remarkable response to crizotinib in a patient with advanced lung adenocarcinoma harboring the MPRIP-ROS1 fusion gene: A case report","authors":"Yasuyuki Kishikawa, Kohei Otsubo, Daisuke Shibahara, Yoshimasa Shiraishi, Yasuto Yoneshima, Eiji Iwama, Isamu Okamoto","doi":"10.1016/j.rmcr.2025.102243","DOIUrl":null,"url":null,"abstract":"<div><div>For patients with advanced non-small cell lung cancer (NSCLC), genetic testing is crucial to identify alterations in targetable driver genes. ROS1-tyrosine kinase inhibitors have shown efficacy against NSCLC with common <em>ROS1</em> fusion genes, but the impact of rare fusion partners on therapeutic outcomes is not well understood. Here, we describe a 75-year-old female with advanced lung adenocarcinoma who was treated with crizotinib after the identification of the extremely rare <em>MPRIP-ROS1</em> fusion. Despite stepwise dose reductions due to adverse effects, the patient exhibited a significant tumor response to crizotinib. The sustained response, even at reduced doses, highlights the potential for targeted therapies in managing NSCLC with <em>MPRIP-ROS1</em> fusion. This case also underscores the importance of comprehensive genomic profiling using hybrid capture-based next-generation sequencing to identify rare driver gene alterations that may not be detected by conventional target sequencing-based methods.</div></div>","PeriodicalId":51565,"journal":{"name":"Respiratory Medicine Case Reports","volume":"56 ","pages":"Article 102243"},"PeriodicalIF":0.7000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Respiratory Medicine Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213007125000796","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}

引用次数: 0

Abstract

For patients with advanced non-small cell lung cancer (NSCLC), genetic testing is crucial to identify alterations in targetable driver genes. ROS1-tyrosine kinase inhibitors have shown efficacy against NSCLC with common ROS1 fusion genes, but the impact of rare fusion partners on therapeutic outcomes is not well understood. Here, we describe a 75-year-old female with advanced lung adenocarcinoma who was treated with crizotinib after the identification of the extremely rare MPRIP-ROS1 fusion. Despite stepwise dose reductions due to adverse effects, the patient exhibited a significant tumor response to crizotinib. The sustained response, even at reduced doses, highlights the potential for targeted therapies in managing NSCLC with MPRIP-ROS1 fusion. This case also underscores the importance of comprehensive genomic profiling using hybrid capture-based next-generation sequencing to identify rare driver gene alterations that may not be detected by conventional target sequencing-based methods.

查看原文本刊更多论文

克唑替尼对携带mip - ros1融合基因的晚期肺腺癌患者的显著疗效：1例报告

对于晚期非小细胞肺癌（NSCLC）患者，基因检测对于识别可靶向驱动基因的改变至关重要。ROS1-酪氨酸激酶抑制剂已显示出对具有常见ROS1融合基因的NSCLC的疗效，但罕见的融合伴侣对治疗结果的影响尚不清楚。在这里，我们描述了一位75岁的晚期肺腺癌女性患者，在发现极其罕见的mip - ros1融合后接受克唑替尼治疗。尽管由于不良反应而逐步减少剂量，但患者对克唑替尼表现出显着的肿瘤反应。即使在减少剂量的情况下，持续的反应也突出了靶向治疗mrip - ros1融合治疗NSCLC的潜力。这个案例也强调了综合基因组分析的重要性，利用基于杂交捕获的下一代测序来识别罕见的驱动基因改变，而传统的基于靶标测序的方法可能无法检测到这些改变。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊